Thus, CDC25-inhibitors targeting either CDC25A or Cdc25B may have the useful property of exhibiting anti-tumor activity in those cancers overproducing these phosphatases without inducing the deleterious GI side effects associated with radiation and chemotherapy. This evidence concerns the gene CDC25C and neoplasm.